Dx&Vx

IR Letter

(Jan. 2025)

Dx&Vx Business Roadmap



Dx

Medical Diagnostics

Dx&Vx's genomic diagnostics and in vitro diagnostics contribute to reducing healthcare costs and improving treatment outcomes. Genomic diagnostic technologies enable more precise and personalized treatments, combined with new drug developments, driving innovation in the medical field. Our companion diagnostic services enhance the efficacy of both our own and third-party drug developments, minimizing side effects and facilitating the development of personalized treatment options for patients.

- Genomic Diagnostics
- In Vitro Diagnostics and CDMO
- Genomics CRO
- Companion Diagnostic Services (CliDex)

HFF

Consumer Healthcare

Using our diagnostic technologies, we provide integrated consumer healthcare solutions based on the microbiome for disease prevention, treatment, and management. Our services include health functional foods for prevention, general pharmaceuticals and prescription drugs for treatment, and products for lifestyle and hygiene management. We target the global market and continue to achieve high sales growth.

- Microbiome-based Therapeutic Adjuncts
- Nutrition Products
- Domestic and International CSO
- Functional Skincare/Personal Hygiene Products

Vx

Drug Development

We have established a comprehensive drug development pipeline, including OVM-200, an immuno-oncology agent, mRNA cancer vaccines, small-molecule compounds (oral obesity treatments), infectious disease vaccines and therapeutics, and other groundbreaking biotech projects. From 2026 onward, the outcomes of our R&D efforts and the commercialization of these initiatives are expected to materialize, enabling us to establish a virtuous cycle of revenue generation and reinvestment in clinical development.

- Microbiome-based Drug Development
- ROP and mRNA Cancer Vaccines
- Cancer Antibody Drugs, Synthetic Organic Drugs
- Ophthalmic Disease Treatment Drugs

DH

Digital Healthcare

Dx&Vx is on the verge of launching K-hub, a bio-pharmaceutical portal, combined with our genomic analysis platform and telemedicine services. We aim to shift from a treatment-centric to a prevention and management-focused approach in healthcare services, ultimately aiming to develop a Clinical Decision Support System (CDSS) to assist medical professionals in their decision-making.

- K-hub
- Telemedicine Services
- AI-based Drug Development Platform
- Smart Diagnostic Devices

Performance Summary for December 2024

- Signed a licensing agreement with Oxford Vacmedix (OVM) in the UK for the cancer vaccine 'OVM-200'
- Entered into a licensing agreement with Stanford University in the US for the development of a universal COVID vaccine
- Established a joint research agreement with LUKA AICell for next-generation antiviral platform technologies
- Signed a patent agreement for long-term storage of mRNA vaccine materials at room temperature
- Scheduled to participate in both the JPMorgan Healthcare Conference and Biotech Showcase in January 2025
- Initiated formal discussions with global pharmaceutical companies to establish partnerships for oral GLP-1 obesity treatments

Drug Development

Signed a licensing agreement with Oxford Vacmedix (OVM) in the UK for the cancer vaccine 'OVM-200'

On December 12, 2024, we signed a licensing agreement with Oxford Vacmedix (OVM) in the UK for the acquisition of rights to the cancer vaccine "OVM-200." Through this agreement, we have secured the rights to develop and commercialize OVM-200 in South Korea, China (including Hong Kong, Macau, and Taiwan), and India. We are now set to advance clinical trials outside the UK. OVM-200 is a therapeutic vaccine designed to eliminate cancer cells and enable immune cells to remember and prevent recurrence of cancer. Animal studies have also demonstrated its potential for cancer prevention, suggesting the possibility of development as a prophylactic cancer vaccine.OVM-200 utilizes recombinant overlapping peptide(ROP) technology to enhance immune efficacy and specifically targets Survivin, a protein expressed in various cancer types. This makes it distinct from existing vaccines. Currently, it has completed Phase 1a clinical trials in the UK and is undergoing Phase 1b, with interim results expected in the first half of next year. We plan to conduct clinical trials and commercialize OVM-200 domestically and internationally, while also exploring opportunities to secure additional rights in the Japanese market.

Entered into a licensing agreement with Stanford University in the US for the development of a universal COVID vaccine

On December 16, 2024, we secured the global rights for the research, development, and commercialization of a universal COVID-19 vaccine technology from Stanford University. This innovative vaccine technology, utilizing nanoparticle-based design, distinguishes itself from conventional mRNA vaccines and can be developed into convenient forms for oral or intranasal administration. The vaccine was invented by Professor Peter Kim of Stanford University's Department of Biochemistry, a world-renowned authority in the biotech industry. Professor Kim was the first to elucidate the mechanism of HIV cell fusion, earning a Nobel Prize nomination, and has served as the head of research at Merck, a leading multinational pharmaceutical company. This agreement was realized through the persistent efforts and trust-building of COREE Group Chairman Chong-Yoon Lim. The pipeline has successfully completed Phase 1 clinical trials in the United States and South Africa. Based on these results, we plan to advance to global Phase 2 clinical trials. By leveraging room-temperature storage technology and developing non-invasive formulations, we aim to enhance accessibility to vaccines and contribute to global public health by providing effective COVID-19 prevention solutions.

Established a joint research agreement with LUKA AICell for next-generation antiviral platform technologies

On December 16, 2024, we signed a joint research agreement with LUKA AICell to develop next-generation antiviral platform technologies. Through this agreement, we will collaborate on LUKA AICell's LEAD peptide technology and secure ownership of the research outcomes. Furthermore, upon entering a technology transfer agreement for commercialization, we will be granted the status of preferred negotiation partner for specific indications. LEAD peptide therapeutics act as antivirals by recognizing and attaching to the surfaces of small viruses, such as coronaviruses (less than 200 nanometers in diameter), and subsequently destroying them. This innovative mechanism specifically targets the curvature of lipid-based viral surfaces without affecting normal cells. Through this joint research, we plan to rapidly conduct studies on specific indications and preclinical toxicity evaluations to expedite the transition to clinical trials.

Signed a patent agreement for long-term storage of mRNA vaccine materials at room temperature

On December 17, 2024, we signed an exclusive license agreement with POSTECH (Pohang University of Science and Technology) for a patented mRNA vaccine material capable of long-term storage at room temperature. Through this agreement, we secured global exclusive commercialization rights for the mRNA platform, which also has applications in nucleic acids such as DNA, offering diverse commercialization opportunities. While mRNA vaccines are faster to develop and more effective than traditional vaccines, they face challenges such as ultra-low temperature storage requirements and limited shelf life. This patented technology addresses these limitations and is regarded as a game-changer in the mRNA industry. Building on this breakthrough, we are actively preparing promotional and sales efforts for global events such as the JP Morgan Healthcare Conference and Biotech Showcase. Additionally, we plan to pursue a sublicensing business model by collaborating with pharmaceutical developers and CMO companies.

Drug Development

Scheduled to participate in both the JPMorgan Healthcare Conference and Biotech Showcase in January 2025

We are scheduled to participate in the JP Morgan Healthcare Conference and Biotech Showcase, held in San Francisco, USA, from January 13 to 15, 2025. These events bring together global pharmaceutical companies, investors, and biotech firms to discuss R&D achievements, investment opportunities, and partnerships. During the events, we will share our research and development milestones, build partnerships, and explore investment opportunities. We plan to showcase our key pipelines, including the oral obesity treatment (GLP-1 RA), the cancer vaccine (OVM-200), the universal NGS diagnostic platform, and advanced biomaterial technologies. Notably, in collaboration with the POSTECH faculty, we will present the world's only mRNA vaccine platform designed for ultra-long-term room-temperature storage (ARPA-H project).Through this presentation, we aim to highlight the transformative potential of this technology to revolutionize global vaccine distribution and storage. Additionally, we intend to discuss sublicensing opportunities with global stakeholders.

Initiated formal discussions with global pharmaceutical companies to establish partnerships for oral GLP-1 obesity treatments

We have initiated discussions with global pharmaceutical companies to establish partnerships for our oral GLP-1 obesity treatment. Currently, the treatment is undergoing preclinical trials, which are expected to be completed next year, with plans to enter clinical stages in the first quarter of 2026. Our goal is to secure early-stage licensing agreements. Amid heightened market expectations following the recent $2 billion licensing agreement between Merck in the United States and Hansoh Pharma in China, our pipeline has also attracted significant interest from global pharmaceutical companies and investors. In January, we will participate in the JP Morgan Healthcare Conference and Biotech Showcase to introduce the innovative technology and research achievements of our GLP-1 obesity treatment. Through these events, we aim to expand partnerships and attract investments.